Iranian Journal of Radiology

Published by: Kowsar

HER2-Positive Breast Cancer: Tumor-to-Liver SUV Ratio is the Best Parameter for Detection in F-18 FDG-PET/CT

Yoshifumi Noda 1 , Satoshi Goshima 1 , * , Hiroshi Kawada 1 , Nobuyuki Kawai 1 , Hiromi Koyasu 1 and Masayuki Matsuo 1
Authors Information
1 Department of Radiology, Gifu University Hospital, Gifu University, Gifu, Japan
Article information
  • Iranian Journal of Radiology: July 2017, 14 (3); e41928
  • Published Online: February 19, 2017
  • Article Type: Research Article
  • Received: August 30, 2016
  • Revised: December 13, 2016
  • Accepted: February 3, 2017
  • DOI: 10.5812/iranjradiol.41928

To Cite: Noda Y, Goshima S, Kawada H, Kawai N, Koyasu H, et al. HER2-Positive Breast Cancer: Tumor-to-Liver SUV Ratio is the Best Parameter for Detection in F-18 FDG-PET/CT, Iran J Radiol. 2017 ; 14(3):e41928. doi: 10.5812/iranjradiol.41928.

Copyright © 2017, Tehran University of Medical Sciences and Iranian Society of Radiology. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Fernandez-Morales LA, Segui MA, Andreu X, Dalmau E, Saez A, Pericay C, et al. Analysis of the pathologic response to primary chemotherapy in patients with locally advanced breast cancer grouped according to estrogen receptor, progesterone receptor, and HER2 status. Clin Breast Cancer. 2007; 7(7): 559-64[DOI][PubMed]
  • 2. Tran B, Bedard PL. Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Res. 2011; 13(6): 221[DOI][PubMed]
  • 3. Hugh J, Hanson J, Cheang MC, Nielsen TO, Perou CM, Dumontet C, et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol. 2009; 27(8): 1168-76[DOI][PubMed]
  • 4. Lam SW, Jimenez CR, Boven E. Breast cancer classification by proteomic technologies: current state of knowledge. Cancer Treat Rev. 2014; 40(1): 129-38[DOI][PubMed]
  • 5. Ross JS, Fletcher JA. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol. 1999; 112(1 Suppl 1)-67[PubMed]
  • 6. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005; 23(16): 3676-85[DOI][PubMed]
  • 7. Untch M, Fasching PA, Konecny GE, Hasmuller S, Lebeau A, Kreienberg R, et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol. 2011; 29(25): 3351-7[DOI][PubMed]
  • 8. Hustinx R, Benard F, Alavi A. Whole-body FDG-PET imaging in the management of patients with cancer. Semin Nucl Med. 2002; 32(1): 35-46[DOI][PubMed]
  • 9. Scott AM. Current status of positron emission tomography in oncology. Intern Med J. 2001; 31(1): 27-36[PubMed]
  • 10. Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF, et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002; 20(2): 379-87[DOI][PubMed]
  • 11. Groheux D, Giacchetti S, Moretti JL, Porcher R, Espie M, Lehmann-Che J, et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011; 38(3): 426-35[DOI][PubMed]
  • 12. Buck A, Schirrmeister H, Kuhn T, Shen C, Kalker T, Kotzerke J, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging. 2002; 29(10): 1317-23[DOI][PubMed]
  • 13. Osborne JR, Port E, Gonen M, Doane A, Yeung H, Gerald W, et al. 18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis. J Nucl Med. 2010; 51(4): 543-50[DOI][PubMed]
  • 14. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Modern Pathol Official J United States Can Acad Pathol. 1998; 11(2): 155-68
  • 15. Perez EA, Roche PC, Jenkins RB, Reynolds CA, Halling KC, Ingle JN, et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc. 2002; 77(2): 148-54[DOI][PubMed]
  • 16. Huber KE, Carey LA, Wazer DE. Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy. Semin Radiat Oncol. 2009; 19(4): 204-10[DOI][PubMed]
  • 17. Garcia Fernandez A, Chabrera C, Garcia Font M, Fraile M, Lain JM, Gonzalez S. . Differential patterns of recurrence and specific survival between luminal A and luminal B breast cancer according to recent changes in the 2013 St Gallen immunohistochemical classification. Clinical & translational oncology. 2014;
  • 18. Koolen BB, Vrancken Peeters MJ, Wesseling J, Lips EH, Vogel WV, Aukema TS, et al. Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2012; 39(12): 1830-8[DOI][PubMed]
  • 19. Koolen BB, Pengel KE, Wesseling J, Vogel WV, Vrancken Peeters MJ, Vincent AD, et al. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer. Breast. 2013; 22(5): 691-7[DOI][PubMed]
  • 20. Kumar R, Chauhan A, Zhuang H, Chandra P, Schnall M, Alavi A. Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat. 2006; 98(3): 267-74[DOI][PubMed]
  • 21. Koo HR, Park JS, Kang KW, Cho N, Chang JM, Bae MS, et al. 18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes. Eur Radiol. 2014; 24(3): 610-8[DOI][PubMed]
  • 22. Jo JE, Kim JY, Lee SH, Kim S, Kang T. Preoperative 18F-FDG PET/CT predicts disease-free survival in patients with primary invasive ductal breast cancer. Acta Radiol. 2015; 56(12): 1463-70[DOI][PubMed]
  • 23. Hasebe T, Tsuda H, Hirohashi S, Shimosato Y, Tsubono Y, Yamamoto H, et al. Fibrotic focus in infiltrating ductal carcinoma of the breast: a significant histopathological prognostic parameter for predicting the long-term survival of the patients. Breast Cancer Res Treat. 1998; 49(3): 195-208[PubMed]
  • 24. Van den Eynden GG, Smid M, Van Laere SJ, Colpaert CG, Van der Auwera I, Bich TX, et al. Gene expression profiles associated with the presence of a fibrotic focus and the growth pattern in lymph node-negative breast cancer. Clin Cancer Res. 2008; 14(10): 2944-52[DOI][PubMed]
  • 25. Parkin J, Cohen B. An overview of the immune system. Lancet. 2001; 357(9270): 1777-89[DOI][PubMed]
  • 26. Bural GG, Torigian DA, Chen W, Houseni M, Basu S, Alavi A. Increased 18F-FDG uptake within the reticuloendothelial system in patients with active lung cancer on PET imaging may indicate activation of the systemic immune response. Hell J Nucl Med. 2010; 13(1): 23-5[PubMed]
  • 27. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med. 2007; 48(6): 932-45[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments